# Francesco Dotta

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/francesco-dotta/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,925 |
| Field | Diabetes and associated disorders |
| h-index | 60 |
| i10-index | 180 |
| Last Known Institution | University of Siena |
| OpenAlex ID | https://openalex.org/A5069364785 |
| ORCID iD | https://orcid.org/0000-0003-4947-7478 |
| Works | 386 |

## Researcher papers

- [NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1](https://scholariq.org/papers/new-onset-diabetes-after-transplantation-2003-international-consensus/)
- [Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial](https://scholariq.org/papers/oral-semaglutide-versus-empagliflozin-in-patients-with-type-2-diabetes/)
- [Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled/)
- [Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial](https://scholariq.org/papers/effects-on-the-incidence-of-cardiovascular-events-of-the-addition-of/)
- [Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled-3/)
- [Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes](https://scholariq.org/papers/abnormal-neutrophil-signature-in-the-blood-and-pancreas-of-presymptomatic-and/)
- [Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/anti-interleukin-21-antibody-and-liraglutide-for-the-preservation-of-cell/)

## Researcher topics

- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [MicroRNA in disease regulation](https://scholariq.org/topics/microrna-in-disease-regulation/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Researcher university

- [University of Siena](https://scholariq.org/institutions/university-of-siena/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.